Nanobiotix S.A.. (1/16/19). "Press Release: Nanobiotix Plans to Conduct Registered Public Offering in the United States". Paris & Cambridge, MA.

	Region	United States (USA)
	Organisation	Nanobiotix S.A. (Euronext Paris: NANO, Nasdaq: NBTX)
	Group	Nanobiotix (Group)
	Organisation 2	Securities and Exchange Commission (SEC) (US)
	Group	United States (govt)
	Product	investment banking
	Product 2	nanomedicine
	Index term	Nanobiotix–SEVERAL: investment, 201901– filing of Form F-1 for registered public offering of shares + ADSs in US conditions to be determined later
	Person	Gaubert, Sarah (Nanobiotix 201603 Head Communication + Public Affairs)
	Person 2	Janic, Marion (RooneyPartners 201702 Partner joined 2008)

NANOBIOTIX SA (Euronext : NANO – ISIN : FR0011341205) announced today that it plans to conduct a registered public offering of its ordinary shares, including in the form of American Depositary Shares (ADSs) in the United States, and has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission. The timing, number of new ordinary shares and ADSs to be issued, the price of such shares and ADSs, and the other terms of the proposed offering have not yet been determined.

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933. This press release does not, and is not intended to, constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

***

About NANOBIOTIX

Incorporated in 2003, Nanobiotix is a late clinical-stage nanomedicine company pioneering new approaches to significantly change patient outcomes by bringing nanophysics to the heart of the cell.

Nanobiotix is listed on the regulated market of Euronext in Paris (Euronext: NANO / ISIN: FR0011341205; Bloomberg: NANO: FP). The Company’s headquarters are based in Paris, France, with a U.S. affiliate in Cambridge, MA, and European affiliates in Spain and Germany.

Contacts Nanobiotix

Sarah Gaubert Director, Communication & Public Affairs +33 (0)1 40 26 07 55 [email protected] / [email protected]

Noël Kurdi Director, Investor Relations +1 (646) 241-4400 [email protected] / [email protected]

Ricky Bhajun Investor Relations Europe +33 (0)1 79 97 29 99 [email protected] / [email protected]

Media relations

France - Springbok Consultants Marina Rosoff +33 (0)6 71 58 00 34 [email protected]

United States – RooneyPartners Marion Janic +1 (212) 223-4017 [email protected]

Record changed: 2023-06-05